Irinotecan Hcl Aqvida (Irinotecan Hydrochloride)

• Irinotecan Hydrochloride is used in oncology to target colorectal cancer and related disease states.
• Colorectal cancer: improves response rates when combined with other chemotherapeutic agents.
• Metastatic colorectal cancer: provides therapeutic benefit in first‑line or later‑line regimens.
• Advanced colorectal cancer: used as part of combination therapy to extend progression‑free survival.

• Irinotecan Hydrochloride is a topoisomerase I inhibitor. After intravenous administration, it is converted to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex, preventing the re‑ligation of single‑strand breaks during DNA replication. This inhibition leads to accumulation of DNA damage, triggering apoptosis in rapidly dividing tumor cells.

Irinotecan Hydrochloride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Diarrhea: often severe and may require supportive care.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: may be managed with anti‑emetics.
• Fatigue: general tiredness experienced during treatment.
• Alopecia: hair loss that is usually reversible.
• Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects

• Severe neutropenic infection: febrile neutropenia requiring immediate medical attention.
• Life‑threatening diarrhea: may lead to dehydration and electrolyte imbalance.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Cardiac toxicity: rare cases of arrhythmia or myocardial ischemia.

• When using Irinotecan Hydrochloride, clinicians should consider several safety measures.
• Dose adjustment: modify dose in patients with hepatic impairment.
• Monitoring: perform regular complete blood counts and liver function tests.
• Hydration: ensure adequate fluid intake to mitigate diarrhea risk.
• Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan Hydrochloride can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure.
• UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia.
• High‑dose irinotecan with other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): monitor INR for bleeding risk.
• Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea.
• Immunosuppressants (e.g., corticosteroids): increase infection susceptibility.